Syros is driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, and we aim to develop new standards of care for the frontline treatment of patients with hematologic malignancies. We are currently developing tamibarotene for genomically defined subsets of MDS and AML patients.

View Tamibarotene View SY-2101 View SY-5609

Latest News

View All News

Latest Financial Results

Q3 2023

Quarter Ended Sep 30, 2023

Latest Annual Report

For Year Ending December 31, 2022

View Annual Report

Stock Information

Syros Pharmaceuticals, Inc.

Symbol

Nasdaq: SYRS

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARĪ± agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression.

Latest Presentation

Investor Presentation

Download

Leadership

Our people are our backbone. Touting years of experience in a variety of fields, our leadership team is the source of our success.

View Management Team View Board of Directors

IR Contact Information

Investor Relations

Syros Pharmaceuticals
Karen Hunady
Director of Corporate Communications & Investor Relations
khunady@syros.com

Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com

Transfer Agent

Computershare Trust Company, N.A.